Buprenorphine Induction/maintenance In Opiate Dependent Patients With Mood Disorders | 108106
Journal of Addiction Research & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: Buprenorphine (a partial opiate agonist/antagonist) is approved for the treatment of opiate
use disorder. Buprenorphine effects the mood modulation through its agonist/antagonist effects on opiate
receptors-Delta (antidepressant effect), Kappa (stress, dissociative/hallucinogenic effects), mu (euphoria) and
Nociceptin (anxiety, depression). Mood disorders used for this study: Bipolar disorders, major depressive
disorders, anxiety disorders and PTSD. Buprenorphine induction/maintenance for opioid dependent patients
who also have a significant mood disorder presents a special challenge for clinicians working with such
complex patients. This study reports the experience in inducting/maintaining Buprenorphine on 250 patients
with a primary diagnosis of mood disorder who were also dependent on opiates. Can Buprenorphine (a
partial opiate agonist/antagonist) be used as the sole medication for patients with primary mood disorders
who also have opiate addiction?
Method: 250 patients with primary mood disorder diagnosis who had presented for treatment of opiate
addiction were inducted/maintained on Buprenorphine only for the first two weeks of treatment. Additional
mood stabilizers or antidepressants were added only if there were continued mood issues while being stable
Conclusion: Our study indicates that for a significant cohort of patients with primary diagnosis of mood
disorders and opiate addiction, Buprenorphine alone might be sufficient to manage both psychiatric
symptoms and opiate addiction. Using charts and graphs, our poster presentation will give details of the data
from the study of 250 patients involved in the study, including our recommendations for clinical practice to
manage patients with co-morbid psychiatric disorders and opiate addiction.
Hassan S Dinakar has pursued his Psychiatry and Addiction Training at New York Medical College. He is Board Certified in Psychiatry and Neurology while also being Board certified in Addiction Medicine. He was an Associate Professor of Psychiatry at New York University School of Medicine until 2006 and is currently working as an Associate Professor at Frank H Netter School of Medicine at Quinnipiac University, Hamden, CT, USA. He is an Associate Medical Director with the Hartford HealthCare working at Meriden, CT. He has made several presentations and has published several articles dealing with mental health and addiction issues.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals